Search

Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman, Langerhans Histiocytosis), who do not harbor the BRAF V600 mutation. Cobimetinib is an oral inhibitor of MEK1 and MEK2 currently approved to treat melanoma. This designation was granted based on data submitted by MSK, in collaboration with Genentech, a member of the Roche Group, from a phase II trial of single-agent cobimetinib for adults with histiocytic disorders (published in Nature in March 2019 by Eli Diamond, MD; Omar Abdel-Wahab, MD; and David Hyman, MD).

… Wednesday, October 2, 2019 Bottom Line: Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman

Get to know Ashley Chui, a chemical biology graduate student in the Sloan Kettering Institute.

… Monday, March 23, 2020 Summary As part of Women’s History Month, we are profiling some of MSK’s star female graduate students and postdoctoral fellows training to be leaders in their fields. Ashley Chui is a graduate student in the Bachovchin lab  in the Sloan Kettering Institute. When and how did you

Joan Argetsinger Steitz, PhD, Sterling Professor of Molecular Biophysics and Biochemistry at Yale School of Medicine, will also be honored with the 2021 Honorary Degree and the MSK Medal for Outstanding Contributions to Biomedical Research.

… Wednesday, May 19, 2021 VIDEO | MSK Tassel Turn 2021 MSK Tassel Turn 2021 Video Details During a virtual commencement ceremony on Wednesday, May 19, 2021, at 3:00 p.m. et, Memorial Sloan Kettering Cancer Center (MSK) will recognize seven Gerstner Sloan Kettering (GSK) 2021 graduates and honor Joan Argetsinger

A low-dose radiation approach could help more patients avoid side effects of treatment for head and neck cancer.

… Thursday, January 20, 2022 Robert Rosenfeld thought the lump he felt in his neck in late 2018 was just a symptom of a cold that wouldn’t go away. He visited an ear, nose, and throat specialist who saw nothing upon first examination, but Robert knew something was wrong and asked for a CT scan. The specialist

Several MSK physicians and researchers presenting during the plenary sessions.

… Thursday, April 8, 2021 Thousands of oncology experts from around the world will tune in April 10-15 for the American Association for Cancer Research’s (AACR) Annual Meeting: Week 1 . The meeting is the first of two virtual meetings, with clinical trial plenary sessions, clinical trial poster sessions

A surprising discovery linking the hormone insulin to skin pigmentation offers fresh insights into how animal bodies take shape.

… Thursday, May 24, 2018 Summary Scientists at the Sloan Kettering Institute have made a surprising find about how the hormone insulin contributes to skin pigmentation in fish. The discovery may have implications for human cancer. If you’re a zebra, you want your stripes in order. Come to the savannah

Researchers have created tiny structures called organoids from patients’ prostate tumors. These organoids will allow the study of tumors in greater detail and enable correlation of genetic mutations with drug response.

… Thursday, September 4, 2014 Summary Researchers have created tiny structures called organoids from patients’ prostate tumors. These organoids will allow the study of tumors in greater detail and enable correlation of genetic mutations with drug response. An international team of researchers led by Memorial

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments.

… Tuesday, January 18, 2022 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Francesca M. Gany Named a 2022 Grant Recipient by Prevent Cancer Foundation Francesca M. Gany Francesca M. Gany, MD, MS , Chief, Immigrant Health and Cancer Disparities Service, was

Along with founding partner Equinox, Cycle for Survival begins its signature team stationary-cycling events this week in New York City. 100% of funds raised go directly to rare cancer research at Memorial Sloan Kettering Cancer Center (MSK).

… Tuesday, March 7, 2023 Cycle for Survival, the movement to beat rare cancers, is launching its annual team stationary-cycling events in 15 locations across the country this weekend in New York City. More than 20,000 riders are expected to participate in person and virtually this March, April, and May

If you've been treated for soft tissue sarcoma, a recurrence may be a big concern for you. Here's what MSK's sarcoma experts think you should know about the disease coming back.

… Tuesday, July 17, 2018 Summary Memorial Sloan Kettering experts share information and tips for people who are worried about soft tissue sarcoma coming back. Fear of the cancer coming back is common among people who’ve recently been treated for soft tissue sarcoma. Most recurrences tend to happen within